Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 60,0 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 90,0 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 120,0 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains apixaban 5,0 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains apixaban 2,5 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - capsules - see ingredients - each capsule contains dutasteride 0,5 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline hydrochloride capsules are indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute rec

Yhdysvallat - englanti - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - cyanocobalamin is indicated for vitamin b12 deficiencies due to malabsorption which may be associated with the following conditions: - addisonian (pernicious) anemia - gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy - fish tapeworm infestation - malignancy of pancreas or bowel - folic acid deficiency it may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see drug interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. such measures remove the need for long-term administration of cyanocobalamin. requirements of vitamin b12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - #n/a - not indicated - none

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - #n/a - not indicated - none